New Super Herceptin is here!

Options
73gr
73gr Member Posts: 459
New Super Herceptin is here!

Comments

  • 73gr
    73gr Member Posts: 459
    edited January 2008

     Genentech's super-Herceptin®, trastuzumab-DM1, entering the clinic for
    treatment of HER2-positive breast cancer. Trastuzumab-DM1 uses the
    Herceptin antibody to target ImmunoGen's maytansinoid cell-killing agent
    DM1 to breast tumors, causing complete tumor regression in all mouse
    trials, whereas Herceptin by itself only slowed growth. The modified
    antibody was even active in Herceptin-resistant tumors.

    Description Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies: anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative).

    Development Status A Phase II clinical trial evaluating T-DM1 for HER2-postive metastatic breast cancer is ongoing.

    This molecule is being developed in collaboration with F. Hoffmann-La Roche and ImmunoGen, Inc.

    Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

    National Institutes of Health Website: www.clinicaltrials.gov

    January 2008

     http://www.gene.com/gene/pipeline/status/oncology/tdm1/

    http://www.gene.com/gene/medcom/index.jsp

  • LittleFlower
    LittleFlower Member Posts: 405
    edited January 2008

    Lorenzo,

    Thank you so much for posting this very promising information!  It is studies like this that give me hope and strength to go on each and every day!

    Thanks

    LittleFlower

  • Anonymous
    Anonymous Member Posts: 1,376
    edited January 2008

    When will they be able to try this on all stage 4 ladies? 

Categories